[{"orgOrder":0,"company":"Akron Biotech","sponsor":"Synairgen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Interferon Beta-1A","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Akron Biotech \/ Synairgen","highestDevelopmentStatusID":"8","companyTruncated":"Akron Biotech \/ Synairgen"},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Octapharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Virally inactivated human AB serum","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Akron Biotech \/ Octapharma","highestDevelopmentStatusID":"1","companyTruncated":"Akron Biotech \/ Octapharma"},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Vor Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Engineered Human Stem Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Akron Biotech \/ Vor Bio","highestDevelopmentStatusID":"7","companyTruncated":"Akron Biotech \/ Vor Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Akron Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : This collaboration strengthens Akron’s portfolio of off-the-shelf gene editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene modified cell therapies including VOR33.

                          Brand Name : VOR33

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          March 22, 2022

                          Lead Product(s) : Engineered Human Stem Cell Therapy,Ozogamicin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Vor Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Partnership Aims to Enhance Safety of Human Serum from Viruses. Under the agreement, Akron Biotech will produce Human AB Serum converted from Octaplas®, which is Octapharma’s pooled, solvent/detergent treated human plasma product.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 20, 2021

                          Lead Product(s) : Virally inactivated human AB serum

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Octapharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Akron will support the future clinical and commercial development of SNG001 through the provision of its IFN-beta in Synairgen’s formulation.

                          Brand Name : SNG001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 19, 2020

                          Lead Product(s) : Interferon Beta-1A

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Synairgen

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank